Optimizing predictive biomarkers for alzheimer's disease: muscarinic M1 antagonist-induced synaptic signaling disruptions and bee venom intervention through cholinergic modulation and multiregression dose selection.
- DOI
- 10.1007/s11011-025-01663-1
- Published
- 2025 Jul 29
- Container
- Metabolic brain disease
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s11011-025-01663-1,
title = {Optimizing predictive biomarkers for alzheimer's disease: muscarinic M1 antagonist-induced synaptic signaling disruptions and bee venom intervention through cholinergic modulation and multiregression dose selection.},
author = {Al Saihati HA and Alazabi NI and Bakeer RM and Abol-Fetouh GM and Ahmed-Farid OA and Alshedi AF and Alsabeelah NF},
year = {2025},
journal = {Metabolic brain disease},
doi = {10.1007/s11011-025-01663-1},
url = {https://doi.org/10.1007/s11011-025-01663-1}
}RIS
TY - JOUR TI - Optimizing predictive biomarkers for alzheimer's disease: muscarinic M1 antagonist-induced synaptic signaling disruptions and bee venom intervention through cholinergic modulation and multiregression dose selection. AU - Al Saihati HA AU - Alazabi NI AU - Bakeer RM AU - Abol-Fetouh GM AU - Ahmed-Farid OA AU - Alshedi AF AU - Alsabeelah NF PY - 2025 JO - Metabolic brain disease DO - 10.1007/s11011-025-01663-1 UR - https://doi.org/10.1007/s11011-025-01663-1 ER -
APA
HA, A. S., NI, A., RM, B., GM, A., OA, A., AF, A., & NF, A. (2025). Optimizing predictive biomarkers for alzheimer's disease: muscarinic M1 antagonist-induced synaptic signaling disruptions and bee venom intervention through cholinergic modulation and multiregression dose selection.. Metabolic brain disease. https://doi.org/10.1007/s11011-025-01663-1
Source records
- pubmed · retrieved 2026-09-25T22:46:09.229Z